 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for March 28, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| NWS... | Hot Stocks20:05 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. News Corp (NWS) is nearing an agreement to purchase the consumer arm of educational publisher Houghton Mifflin Harcourt (HMHC), The Wall Street Journal's Jeffrey Trachtenberg and Dana Cimilluca reported, citing people familiar with the matter. The deal, which the people said could be announced as early as Monday, would add a portfolio of high-profile novels from authors such as George Orwell, Philip Roth and J.R.R. Tolkien to News Corp's HarperCollins Publishers division, the authors noted. 2. According to U.S. Trade Representative Katherine Tai, the U.S. isn't ready to lift tariffs on Chinese imports in the near future, but might be open to trade negotiations with Beijing, The Wall Street Journal's Bob Davis and Yuka Hayashi reported. Tai said she recognized that the tariffs can exact a toll on U.S. businesses and consumers, though proponents have said they also help shield companies from subsidized foreign competition. 3. Tax Day comes and Tax Day goes, but H&R Block (HRB) might someday be a stock for all seasons, Carleton English wrote in this week's edition of Barron's. H&R Block is diversifying its business following years of underperformance, the author noted. The plan could take longer than expected, though its 5.3% dividend yield means that investors are paid to wait for good things to happen, English added. 4. Comcast (CMCSA) subsidiary Universal's "Nobody" opened to $6.7M domestically as more locations in Los Angeles and the rest of West Coats reopen. Overseas, the movie has amassed $5M. However, the big headline of the weekend internationally was AT&T (T) subsidiary Warner Bros.' "Godzilla vs. Kong," which launched to a pandemic-best $121.8M, including $70.3M in China alone. 5. Welbilt (WBT), AT&T, Coca-Cola (KO), Consolidated Edison (ED), IBM (IBM), Johnson & Johnson (JNJ), Kellogg (K), Procter & Gamble (PG), SL Green Realty (SLG), U.S. Bancorp (USB) and Verizon (VZ) saw positive mentions in this week's edition of Barron's.
|
| BLUE BMY | Hot Stocks15:54 EDT FDA approves Bristol Myers Squibb, Bluebird Bio's Abecma - Bristol Myers Squibb (BMY) and Bluebird Bio (BLUE) announced that the U.S. Food and Drug Administration has approved Abecma as the first B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is a personalized immune cell therapy approved as a one-time infusion with a recommended dose range of 300 to 460 x 106 CAR-positive T cells. As an anti-BCMA CAR T cell therapy, Abecma recognizes and binds to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of BCMA-expressing cells. A network has been created to support rapid and dependable manufacturing of Abecma and ensure capacity to accommodate patient demand. Abecma will be manufactured for each individual patient using the patient's own T cells at Bristol Myers Squibb's cellular immunotherapy manufacturing facility in Summit, New Jersey. The lentiviral vector, which is used to engineer the CAR T cells, was developed by bluebird bio. Due to the specialized nature of administering cell therapy, Abecma will be available at certified treatment centers throughout the country. A Risk Evaluation and Mitigation Strategy program will be implemented at certified centers to support appropriate use of Abecma including training on the management of cytokine release syndrome and neurologic toxicities. Abecma is being jointly developed and commercialized in the U.S. as part of a Co-Development, Co-Promotion and Profit Share Agreement between Bristol Myers Squibb and Bluebird Bio.
|
